The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jun. 19, 2018

Filed:

Mar. 10, 2016
Applicant:

Moerae Matrix, Inc., Morristown, NJ (US);

Inventors:

Cynthia Lander, Mendham, NJ (US);

Colleen Brophy, Nashville, TN (US);

Caryn Peterson, Encinitas, CA (US);

Andrew Luber, Voorhees, NJ (US);

Assignee:

Moerae Matrix, Inc., Morristown, NJ (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 33/24 (2006.01); A61K 45/06 (2006.01); A61K 38/17 (2006.01); A61K 9/00 (2006.01); A61M 11/00 (2006.01); A61M 15/00 (2006.01);
U.S. Cl.
CPC ...
A61K 38/1709 (2013.01); A61K 9/0075 (2013.01); A61K 9/0078 (2013.01); A61K 33/24 (2013.01); A61K 45/06 (2013.01); A61M 11/00 (2013.01); A61M 15/00 (2013.01); A61M 2202/064 (2013.01);
Abstract

Pharmaceutical compositions, systems and methods for treating a non-small cell lung cancer (NSCLC) solid tumor comprising a population of tumor cells are described. In some aspects, administering a pharmaceutical composition comprising a therapeutic amount of a polypeptide having the amino acid sequence YARAAARQARAKALARQLGVAA (SEQ ID NO: 1) or functional equivalent thereof, and a pharmaceutically acceptable carrier, is effective to inhibit a kinase activity in the population of tumor cells and to reduce cancer cell proliferation, to reduce tumor size, to reduce tumor burden, to induce tumor cell death, to overcome tumor chemoresistance, to enhance tumor chemosensitivity, or a combination thereof.


Find Patent Forward Citations

Loading…